Hubei Jumpcan Pharmaceutical Co Ltd banner
H

Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566

Watchlist Manager
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
Watchlist
Price: 27.69 CNY 0.62%
Market Cap: ¥25.5B

EV/FCFF

14.2
Current
79%
More Expensive
vs 3-y average of 8

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
14.2
=
Enterprise Value
¥13.6B
/
Free Cash Flow to Firm
¥1B

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
14.2
=
Enterprise Value
¥13.6B
/
Free Cash Flow to Firm
¥1B

Valuation Scenarios

Hubei Jumpcan Pharmaceutical Co Ltd is trading above its 3-year average

If EV/FCFF returns to its 3-Year Average (8), the stock would be worth ¥15.5 (44% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-44%
Maximum Upside
+116%
Average Upside
33%
Scenario EV/FCFF Value Implied Price Upside/Downside
Current Multiple 14.2 ¥27.69
0%
3-Year Average 8 ¥15.5
-44%
5-Year Average 8.1 ¥15.77
-43%
Industry Average 30.7 ¥59.82
+116%
Country Average 28.8 ¥56.12
+103%

Forward EV/FCFF
Today’s price vs future free cash flow to firm

Not enough data available to calculate forward EV/FCFF

Peer Comparison

All Multiples
EV/FCFF
P/E
All Countries
Close
Market Cap EV/FCFF P/E
CN
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
25.5B CNY 14.2 14.7
US
Eli Lilly and Co
NYSE:LLY
883B USD 153.6 42.8
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 29.4 26.3
CH
Roche Holding AG
SIX:ROG
248.4B CHF 26.4 20.1
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP 35.4 28
US
Merck & Co Inc
NYSE:MRK
270.2B USD 24.5 14.8
CH
Novartis AG
SIX:NOVN
216.3B CHF 19.6 20.7
IE
Endo International PLC
LSE:0Y5F
244.4B USD 1 486.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 44.6 11.8
US
Pfizer Inc
NYSE:PFE
151.8B USD 22 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 12 17.3
P/E Multiple
Earnings Growth PEG
CN
H
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
Average P/E: 21.6
14.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.8
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.3
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
US
Merck & Co Inc
NYSE:MRK
14.8
14%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.8
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.5
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
16%
1.1

Market Distribution

Lower than 71% of companies in China
Percentile
29th
Based on 4 731 companies
29th percentile
14.2
Low
0 — 14.5
Typical Range
14.5 — 57
High
57 —
Distribution Statistics
China
Min 0
30th Percentile 14.5
Median 28.8
70th Percentile 57
Max 307 555.7

Hubei Jumpcan Pharmaceutical Co Ltd
Glance View

In the bustling landscape of China's pharmaceutical industry, Hubei Jumpcan Pharmaceutical Co Ltd stands as a key player, weaving together tradition and modernity. Founded in 1951, this company has curated a journey of evolution—from its roots in the rich tapestry of traditional Chinese medicine to its current standing as a significant contributor to the healthcare sector. Core to Jumpcan's operation is its production and distribution of a diverse array of pharmaceutical products that span across various therapeutic areas, including digestive health, dermatology, and respiratory care. With an adept focus on over-the-counter medications and prescription drugs, Jumpcan effectively meets the health needs of a broad demographic, leveraging both the enduring appeal of traditional remedies and the growing demand for contemporary medical solutions. The business prowess of Jumpcan is deeply entwined with its strategy of innovation and adherence to quality standards, ensuring its pharmaceutical offerings are not only effective but also safe for consumption. Anchored in robust R&D initiatives, the company continues to enhance its product line, incorporating advanced technology and scientific research to produce medicines that align with global quality benchmarks. Furthermore, Jumpcan thrives on an extensive distribution network that spans across China, ensuring widespread accessibility of its products. By maintaining a keen understanding of the market dynamics and consumer preferences, Jumpcan artfully aligns its operations to capitalize on both domestic and international opportunities, thus solidifying its financial standing and perpetuating its growth within the dynamic corridors of the pharmaceutical industry.

Intrinsic Value
21.7 CNY
Overvaluation 22%
Intrinsic Value
Price ¥27.69
H
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett